Back to top
more

Quanterix (QTRX)

(Delayed Data from NSDQ)

$6.08 USD

6.08
702,125

+0.43 (7.61%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $5.96 -0.12 (-1.97%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Thermo Fisher (TMO) to Advance Clinical Research With New Pact

by Zacks Equity Research

Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies.

Zacks Equity Research

Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity

by Zacks Equity Research

Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.

Zacks Equity Research

Align Technologies (ALGN) Brings New Upgrades for Oral Health

by Zacks Equity Research

Align Technologies (ALGN) introduces a series of software innovations to accelerate the digital practice transformation.

Zacks Equity Research

Globus Medical (GMED) Launches NuVasive's NSO in Global Market

by Zacks Equity Research

Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.

Zacks Equity Research

National Vision (EYE) Gains From Store Opening Amid Macro Woes

by Zacks Equity Research

In terms of store expansion, National Vision (EYE) continues to see a sizable new opportunity with growth for the coming years.

Zacks Equity Research

Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio

by Zacks Equity Research

Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.

Zacks Equity Research

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.

Zacks Equity Research

Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs

by Zacks Equity Research

Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.

Zacks Equity Research

Align Technologies (ALGN) Set to Acquire Cubicure GmbH

by Zacks Equity Research

Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.

Zacks Equity Research

Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval

by Zacks Equity Research

Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.

Zacks Equity Research

Abbott (ABT) to Advance Diabetes Care With New Acquisition

by Zacks Equity Research

Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.

Zacks Equity Research

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.

Zacks Equity Research

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.

Zacks Equity Research

Charles River (CRL) Gains From Global Demand Amid FX Woes

by Zacks Equity Research

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.

Zacks Equity Research

Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe

by Zacks Equity Research

Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.

Zacks Equity Research

LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM

by Zacks Equity Research

LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).

Zacks Equity Research

Globus Medical (GMED) Completes NuVasive Merger Agreement

by Zacks Equity Research

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

Zacks Equity Research

ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod

by Zacks Equity Research

The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.

Zacks Equity Research

Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool

by Zacks Equity Research

Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.

Zacks Equity Research

Boston Scientific's (BSX) FARAPULSE System Study Data Positive

by Zacks Equity Research

Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.

Zacks Equity Research

Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod

by Zacks Equity Research

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.